Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement




May
29
Today In Oncology
Behind the Scenes of the 2026 ASCO Annual Meeting
First-Line Sunvozertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations
FDA Approves Durvalumab Plus BCG for High-Risk NMIBC
Local Radiotherapy May Help Control Oligometastatic Breast Cancer
TAILORx and RxPONDER Trials Shift to a Discovery Platform
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo